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Abstract
Objectives: To investigate the effect of ACE inhibitors (ACEi) on the incidence of scleroderma renal crisis (SRC)
when given prior to SRC in the prospectively collected cohort from the European Scleroderma Trial and Research
Group (EUSTAR).
Methods: SSc patients without prior SRC and at least one follow-up visit were included and analyzed regarding
SRC, arterial hypertension, and medication focusing on antihypertensive medication and glucocorticoids (GC).
Results: Out of 14,524 patients in the database, we identified 7648 patients with at least one follow-up. In 27,450
person-years (py), 102 patients developed SRC representing an incidence of 3.72 (3.06–4.51) per 1000 py. In a
multivariable time-to-event analysis adjusted for age, sex, disease severity, and onset, 88 of 6521 patients developed
SRC. The use of ACEi displayed an increased risk for the development of SRC with a hazard ratio (HR) of 2.55 (95%
confidence interval (CI) 1.65–3.95). Adjusting for arterial hypertension resulted in a HR of 2.04 (95%CI 1.29–3.24).
There was no evidence for an interaction of ACEi and arterial hypertension (HR 0.83, 95%CI 0.32–2.13, p = 0.69).
Calcium channel blockers (CCB), angiotensin receptor blockers (ARB), endothelin receptor antagonists, and GC—
mostly in daily dosages below 15 mg of prednisolone—did not influence the hazard for SRC.
Conclusions: ACEi in SSc patients with concomitant arterial hypertension display an independent risk factor for the
development of SRC but are still first choice in SRC treatment. ARBs might be a safe alternative, yet the overall
safety of alternative antihypertensive drugs in SSc patients needs to be further studied.
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Key messages
1) ACE inhibitors display a risk for the development of
SRC in SSc patients
2) Arterial hypertension and ACE inhibitors are
independent risk factors for SRC
3) Regarding SRC, alternative antihypertensive drugs
need to be studied in SSc patients
Introduction
ACE inhibitors (ACEi) are the mainstay of therapy in
scleroderma renal crisis (SRC). Initiation of their use
allowed for major increased survival rates of SRC over
the last decades yet with mostly lasting sequelae [1].
Nevertheless, the incidence of SRC remained almost un-
changed over the last decades and SRC risk factors are
still poorly understood. Among those, the use of ACEi
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in hypertensive SSc patients prior to any SRC episode is
meanwhile contradictorily discussed. While ACEi are
supposed to lower the risk of SRC at the same time as
they lower blood pressure, there are a few data that SRC
outcome is worse in patients with prior ACEi intake.
A prospective online survey demonstrated a worse out-
come in SRC patients when treated with ACEi prior to
SRC onset [2]. On the other hand, pathophysiological rea-
soning cannot explain the phenomenon why a therapeutic
agent should be discouraged when applied in a protective
intention. The need for more valuable data is therefore
often discussed among experts, but respective trials are
rare, mostly retrospective, and difficult to conduct. One
study by Guillevin et al. in as much as 91 patients pointed
into the direction of favoring ACEi for SRC protection but
was unable to draw firm conclusions [3].
Furthermore, besides some well-known factors for the
risk of SRC, arterial hypertension is still discussed as by-
stander or promoting factor leaving the optimal choice
for antihypertensive treatment unanswered.
Arterial hypertension in SSc patients might be present
per se (i.e., independent from SSc itself) or at least in part
due to hyperreninemia with activation of the renin-
angiotensin-aldosterone system (RAAS)—which itself is
discussed as a risk factor for SRC [4]. RAAS activation
might therefore lead to the idea of initiating ACEi therapy.
The use of beta blockers and/or diuretics in the treat-
ment of arterial hypertension in SSc patients is mostly
precluded as they negatively affect the already reduced
peripheral perfusion.
Calcium channel blockers (CCB) used to be the anti-
hypertensive medication of choice in SSc patients due to
their vasodilative effects and improvement in Raynaud’s
phenomenon. Unfortunately, negative effects on, e.g., the
esophagus, by smooth muscle relaxation [5] and sphinc-
ter pressures have been claimed although their clinical
consequences on reflux and potential aspiration remain
uncertain.
In the era of endothelin receptor antagonists (ERA)
used for prevention of digital ulcers, the impact of CCBs
at least in the indication for digital ulcer prevention
might be vanishing. Furthermore, ERAs were supposed
to be helpful in SRC as endothelin expression was shown
to be high in kidney specimen from SRC patients [6].
Yet, they have only rarely been described in SRC case re-
ports without convincing results [7].
The use of glucocorticoids (GC) especially in higher doses
above 15mg/d has long been known as important negative
factor for the development of SRC, and the use of GC dos-
ages above 15mg/d is therefore discouraged [8]. However,
the bias for indication cannot be ruled out in this setting with
more severe patients having a higher propensity to receive
high-dose corticosteroids. In addition, concomitant medica-
tion with, e.g., glucocorticoids in a situation of an activated
RAAS additionally reduces renal flow by inhibiting synthesis
of prostaglandins. Nevertheless, even recent data report on
frequent if not routine use of GC in SSc patients for various
reasons as, e.g., interstitial lung disease or progressive skin af-
fection [9].
Data regarding incidence and influencing factors for
SRC have and will always have limitations: they describe a
very rare phenomenon in a rare disease with heteroge-
neous presentation and ongoing discussion about correct
and/or consensus-driven diagnostic criteria [10]. The cur-
rently published data on possible classification criteria for
SRC reflect this process [11]. The herein proposed core
set of acute onset of hypertension, acute kidney injury, mi-
croangiopathic hemolytic anemia/thrombocytopenia, and
target organ dysfunction is mainly consistent with the
EUSTAR-based definition of SRC.
We therefore set out to analyze the European Sclero-
derma Trials and Research (EUSTAR) database represent-
ing the largest European and in part Extra-European
prospective data collection from SSc patients, hereby fo-
cusing on ACEi, arterial hypertension, other anti-
hypertensive medication, and glucocorticoids with respect
to their influence on SRC.
Methods
Design
The EUSTAR database is a multicenter online database
that contains prospectively collected data from more
than 15,000 SSc patients in more than 200 international
centers. Each patient’s annually scheduled visit for med-
ical purposes is recorded providing longitudinal observa-
tional data. Each participating center has to obtain a
positive ethics vote from their respective local ethical
committee prior to including patients into the EUSTAR
registry.
Patients and medication
SSc patients were included at their first registered visit
(referred to as baseline visit) if they had no reported
SRC at or before this visit and at least one follow-up
visit. Patients without any information about SRC or
with missing visit dates were excluded.
Common EUSTAR definition of SRC is the abrupt on-
set of severe hypertension accompanied by rapidly pro-
gressive renal failure, hypertensive encephalopathy,
congestive heart failure, and/or microangiopathic
hemolytic anemia. Participating centers are expert cen-
ters only, and each EUSTAR center is trained by
EUSTAR-specific courses including the definitions for
disease entities as, e.g., SRC.
We used two different datasets: the so called
“complete” dataset comprising all data within the
EUSTAR database up to November 15, 2017, and a so
called “medication” subset for which medication was
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consistently recorded—i.e., data collected at or after
January 1, 2009, when definite documentation of medi-
cation within the EUSTAR database was started. In ac-
cordance with the complete dataset, the first visit after
this date is referred to as baseline visit and patients with
SRC before or at this baseline visit were excluded. For
sensitivity analysis, the dataset was further reduced to
patients enrolled in or after 2009.
The focus was laid on medication with ACEi, angio-
tensin receptor blockers (ARB), CCB, ERA, phospho-
diesterase-5 (PDE5) inhibitors, and GC. The main ana-
lyses involving medication were based on the medication
dataset.
Statistical analysis
Patient characteristics are reported as median and inter-
quartile range (IQR) or number and percentage of pa-
tients for continuous and categorical data, respectively.
Patients with and without SRC were compared by Wil-
coxon rank-sum tests and chi-squared tests, differences
are presented as Hodges-Lehman median differences
and risk differences with corresponding 95% confidence
intervals (95% CI).
For survival analysis, patients were considered to be at
risk after the baseline visit. The exact time point of SRC
was interpolated between the last visit without and the
first visit with renal crisis. Only visits up to the first SRC
were considered. Patients without SRC were censored at
the last registered visit. Missing time-varying covariates
were handled by carrying the last observation forward.
Patients with missing time-constant variables were ex-
cluded from the analysis.
Mortality is presented using a Kaplan-Meier failure
plot, and the 5-year mortality was calculated using one
minus the Kaplan-Meier estimator with the Greenwood
pointwise standard error. Cumulative incidence of SRC
was calculated using the Aalen-Johansson estimator with
death (without SRC) as competing event.
We fitted cause-specific Cox proportional hazard
models for SRC in which deaths were censored. Results
are reported as hazard ratio (HR) with 95% CI. In sensi-
tivity analyses, we used competing risk regressions with
death (without SRC) as competing event to estimate
sub-hazard ratios (sHR). Univariable models were fitted
for a number of baseline and medication variables. All
variables with a p value < 0.2 and age, sex, disease sever-
ity (whether or not there is diffuse skin involvement),
and the time between onset of scleroderma and baseline
visit were included in a multivariable analysis. Covariates
were allowed to change over time if applicable. In sensi-
tivity analyses, only values at baseline or at any time be-
fore SRC were used.
For further sensitivity analysis, we used propensity
score methods to estimate the effect of ACEi at baseline
or at any time before SRC on the hazard of SRC. Pro-
pensity scores were calculated from a logistic regression
model for ACEi including the same set of covariates as
the multivariable model. A common support was im-
posed by dropping treatment observations outside the
range of the control propensity scores. Three different
methods based on Stata command propensity score
matching were used according to Leuven and Sianesi:
one-to-one matching on the propensity score without
replacement, k-nearest neighbors matching with replace-
ment (with k = 3, k = 5, k = 10) and inverse probability
weighting. Matching was performed with a caliper of
0.01. The matched observations were then used for a
Cox regression with ACEi as the only covariate and ro-
bust standard errors to correct for the clustering based
on the Huber-White sandwich estimator. For inverse
probability weighting, 5% of the treatment observations
at which the propensity score density of the control were
lowest were dropped (trimming). We then calculated
stabilized inverse probability weights and fitted a
weighted Cox regression for ACEi as the only covariate
[12].
For analysis of medication changes with focus on ACEi
only patients in the medication dataset with SRC and
visits before and after SRC were considered.
Results
Patient selection (Fig. 1)
Out of 14,524 eligible SSc patients, 9690 and 7648 pa-
tients were included in the complete and medication
datasets, respectively. One hundred sixty-nine and 102
patients developed SRC in 45,071 and 27,450 person-
years (py), representing an incidence per 1000 py of 3.75
(95% CI 3.22–4.36) and 3.72 (95% CI 3.06–4.51),
respectively.
In the complete dataset (supplementary Table 1), pa-
tients developing SRC over the course of the study were
significantly more often male (40/169 vs 1292/9521, 24
vs 14%, p < 0.001) with a shorter disease duration (de-
fined as onset of first non-Raynaud’s symptom) before
inclusion in the study (3.1 vs 5.2 years, p < 0.001). At
baseline, these patients displayed an SCL-70 antibody
profile (72/158 vs 2962/8926, 46 vs 33%, p = 0.001) and
demonstrated more often diffuse skin involvement (82/
167 vs 2709/9267, 49 vs 29%, p < 0.001), arterial hyper-
tension (63/166 vs 1862/9418, 38 vs 20%, p < 0.001), and
tendon friction rubs (28/166 vs 722/9283, 17 vs 8%, p <
0.001), as well as muscle weakness and atrophy.
Non-SRC patients were observed for a median time of
3.6 years (IQR 1.6 to 6.9) with 4 visits (IQR 2 to 6). Pa-
tients with SRC were observed for a median time of 5.0
years (IQR 2.5–8.4) with 6 visits (IQR 3–8). Median time
to first onset of SRC was 1.7 years (IQR 0.5–4.2). Over
the entire observation period, we documented death in
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patients with SRC (48/169) and without SRC (1025/
9521, 28% vs 11%), leading to a 5-year mortality of
18.6% in SRC patients (95%CI 13.0–26.3%) and 9.5%
(95%CI 8.8–10.3%) in non-SRC patients (Fig. 2).
Patient characteristic medication dataset (Table 1)
Regarding medication, ACEi were given more often in
patients who developed SRC over the course of the study
(34/96 vs 1299/7163, 35 vs 18%, p < 0.001). For all other
medication studied, we did not find any significant
differences.
Median observation time was 3.1 years (1.5 to 5.6) for
patients without SRC and 4.9 years (IQR 2.5–6.2) for pa-
tients that developed SRC. The first SRC was observed
after a median of 1.5 years (IQR 0.5 to 3.4).
Cumulative SRC incidence is negatively influenced by
arterial hypertension and ACEi but not by CCB or GC
Cumulative incidence of SRC was analyzed for the risk
factors of interest, i.e., arterial hypertension, ACEi, CCB,
GC, and ARB (Fig. 3). Death without SRC was treated as
a competing event. Cumulative incidence for SRC was
increased in patients treated with ACEi or suffering ar-
terial hypertension but not for patients treated with CCB
or GC. For the latter, a minor trend could be detected in
the long-term application.
Fig. 1 Patient flow. *Does not sum up as categories are not exclusive
Fig. 2 Kaplan-Meier failure plot for mortality with 95% confidence
intervals of patients with and without scleroderma renal crisis (SRC)
based on the complete dataset
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The effect of ACEi persisted in models adjusted for
potential risk factors using propensity score matching or
probability weighting (supplementary Fig. 1).
Influencing factors for SRC
Potential risk factors for SRC were tested in univariable
Cox proportional hazard models (supplementary Table 2)
and included in a multivariable Cox model if evidence
for an influence was found (Table 2). For the final model
on the medication dataset, 6083 patients were included,
and 78 experienced SRC.
An increased risk for SRC was found for diffuse skin
involvement (hazard ratio (HR) 1.79, 95%CI 1.06–3.02,
p = 0.030), arterial hypertension (HR 2.22, 95%CI 1.34–
3.66, p = 0.002), and ACEi (HR 2.07, 95%CI 1.28–3.36,
p = 0.003).
The results were largely confirmed in sensitivity ana-
lyses where time-varying variables were held constant by
either using the baseline values (supplementary Table 3)
or observation at any time over the follow-up period
(supplementary Table 4), and if only patients enrolled in
or after 2009 were analyzed (supplementary Table 5).
An alternative analysis using competing risk regression
with death as competing event gave similar results with
arterial hypertension and ACEi as most important risk
factors (sHR 2.28 95%CI 1.36–3.81, p = 0.002 and sHR
2.07, 95% CI 1.27–3.38, p = 0.004, respectively) (supple-
mentary Table 6).
Adjustment via propensity score matching or inverse
probability weighting confirmed the effect of ACEi, re-
gardless whether covariates at baseline or at any time
over the course of the study were used (supplementary
Table 7).
Sensitivity analysis suggests ACEi and arterial
hypertension as independent risk factors for SRC
We tested for an interaction of the two most important
risk factors, arterial hypertension and ACEi, by adding
an interaction term to the multivariable Cox propor-
tional hazard model (Table 3). Evidence for an inter-
action was not found (HR of interaction term 0.83,
95%CI 0.32–2.13, p = 0.69) suggesting that ACEi and ar-
terial hypertension were independent risk factors for
SRC.
We also analyzed medication before and after SRC,
i.e., assessed patients that received ACEi at any time
point prior and after SRC. In most cases (49/69), ACEi
were continued after renal crises.
Discussion
Our work analyses the largest cohort of SSc patients
with focus upon potentially influencing medication for
the development of SRC.
To our surprise, ACEi independently and very promin-
ently enhanced the hazard for SRC. Assuming that the
main reason for the prescription of ACEi is arterial
Table 1 Characteristics of medication dataset at baseline. Only the time up to the first SRC is considered
Patients with SRC (N = 102) Patients without SRC (N = 7546) Median # or risk
difference (95% CI)
P value
Median (IQR) or no. of patients (%)
Age (years) 57.3 (48.0 to 67.9) 56.4 (46.0 to 65.7) 1.3 (− 1.3 to 3.9) 0.36
Sex (female) 80/102 (78%) 6484/7546 (86%) − 7% (− 16 to 1%) 0.031
Time between onset of scleroderma and inclusion (y)* 5.0 (1.9 to 10.9) 7.0 (3.1 to 13.2) − 1.3 (− 2.5 to − 0.3) 0.019
Extent of skin involvement 0.005
No skin involvement 4/100 (4%) 306/7312 (4%)
Only sclerodactyly 11/100 (11%) 785/7312 (11%)
Limited cutaneous involvement 41/100 (41%) 4151/7312 (57%)
Diffuse cutaneous involvement 44/100 (44%) 2070/7312 (28%)
Glucocorticoids 37/90 (41%) 2437/6644 (37%) 4% (− 6 to 15%) 0.39
Dose at baseline (if > 0), mg 7.5 (5.0 to 10.0) 5.0 (5.0 to 10.0) 0.0 (0.0 to 2.0) 0.16
Glucocorticoids > 10 mg 5/90 (6%) 295/6644 (4%) 1% (− 4 to 6%) 0.61
Glucocorticoids > 15 mg 3/90 (3%) 171/6644 (3%) 1% (− 3 to 4%) 0.65
ACE inhibitors 34/96 (35%) 1299/7163 (18%) 17% (8 to 27%) < 0.001
Angiotensin receptor blocker 6/96 (6%) 654/7150 (9%) − 3% (− 8 to 2%) 0.33
Calcium channel blockers 50/96 (52%) 3763/7178 (52%) − 0% (− 10 to 10%) 0.95
Endothelin receptor antagonist 12/85 (14%) 727/6165 (12%) 2% (− 5 to 10%) 0.51
PDE5 inhibitors 6/91 (7%) 321/6649 (5%) 2% (− 3 to 7%) 0.44
*Missing data for 10 patients with and 982 patients without SRC
#Generalized Hodges-Lehmann median differences
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hypertension the latter was analyzed separately. We
hereby wanted to rule out arterial hypertension itself as
the main influence for SRC. Contrariwise ACEi and ar-
terial hypertension proved independent risk factors and
even more: both factors add up the risk for SRC. These
results lead us to perform subanalyses regarding other
potentially influencing factors finally confirming the ini-
tial results even more. In line with our main finding are
the results of the QUINS trial [13]. Within this con-
trolled trial, the ACE inhibition by long-term application
of quinapril was not able to control vascular damage in
SSc patients with limited cutaneous disease.
One of the questions is whether our cohort is different
from other SRC cohorts. We found a SRC incidence of
3.72 (3.06–4.51) per 1000 py. Some of the first analyses
by Steen et al. in 1984 could demonstrate an incidence
of as high as 18% within their retrospective cohort of
rapidly progressing SSc patients [14]. Since then SRC in-
cidence considerably declined: In a recent large meta-
analysis, an overall SRC prevalence of 4% was found
Fig. 3 Cumulative incidence of SRC with 95% confidence intervals depending on whether patients have arterial hypertension (AH) based on the
complete dataset or are treated with ACE inhibitors (ACE), calcium channel blockers (CCB), or glucocorticoids (GC) based on the medication dataset
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during the last 30 years consistent with findings from
the EUSTAR group describing a prevalence of 4.2% in
the diffuse cutaneous (dc) SSc group [15, 16]. Mainly,
most SRC risk factors as, e.g., dSSc, male sex, and rapid
disease progression as displayed in our cohort are of
course well-known risk factors for SRC [17, 18] with a
longer duration of disease tending to reduce the risk of
SRC as the counterpart. In addition, glucocorticoids
given in higher dosages have already been described ex-
tensively as negatively influencing SRC incidence and
outcome [19]. Here, our data could demonstrate a
minimal effect of GC only, yet the average dosage was
low with only 3% receiving more than 15 mg of prednis-
olone per day. So most physicians must have imple-
mented this negative impact when deciding for
immunosuppression of any kind. Furthermore, our data
were collected prospectively in a standardized manner
which allows for adequate documentation with only few
missings.
Given a thorough analysis of a well-defined, prospect-
ively collected cohort, what reasoning might at least in
part explain our findings? Possibly, in SSc patients with
long standing ACEi therapy, an aldosterone break-
through mechanism with elevated aldosterone and renin
levels therapy might come into account [20] leading to
further unwanted vasoconstriction and endothelial cell
proliferation. In this case, direct renin inhibition seems
to be an option. Yet, this inhibition was not able to pre-
vent from breakthrough mechanisms so far [21]. Fur-
thermore, renin inhibition has only infrequently been
used in SSc patients [22] which is as well reflected in
our analysis as no EUSTAR patient had received renin
inhibitors.
Therefore, regarding angiotensin II, its direct blockade
appears to be an option, which might guide therapy into
the direction of ARBs. This hypothesis is clearly sup-
ported by our data: as more than 600 patients were
treated with ARBs, we judge the results valuable: In clear
contrast to the use of ACEi, ARBs demonstrated a
slightly positive effect on the hazard of SRC and defin-
itely no negative effect at all.
Other medication analyzed within our cohort had a
neutral effect on SRC occurrence as, e.g., CCBs: they
showed no additional influence in concomitant arterial
hypertension. This is in agreement with a recent analysis
of the Canadian Scleroderma Research Group, which did
not find any association of CCB with SRC [23].
Secondly, some medication was given in few patients
only. ERA for example might have some indication in
SRC treatment as ET receptors can be expressed within
SRC [24] and rare cases with positive effects of ET recep-
tor blocking therapy in SRC have been observed [25]. No
data exist on their preventive potential and our study does
not contribute enough evidence to allow for a clear de-
scription of any influence on SRC incidence in either way.
Overall, our data clearly demonstrate an increased risk
for SRC when ACEi are used in SSc patients prior to the
onset of any SRC. Nevertheless, the significant and inde-
pendent negative influence of arterial hypertension on
the risk of SRC demands antihypertensive treatment.
Unfortunately, the list of acceptable antihypertensive
medications in SSc patients is short and—after removal
of ACEi—mostly CCB and ARBs are left. The large
number of SSc patients with ARB treatment in our co-
hort without a negative signal on SRC incidence might
Table 2 Hazard ratios for renal crisis from a multivariable Cox
proportional hazard model based on the medication dataset. All
variables with p < 0.2 in the univariable analyses were included
No. of renal
crises/patients
Hazard ratio
(95% CI)
P value
Age (per decade) 78/6083 1.06 (0.87–1.28) 0.56
Sex (male) 1.30 (0.74–2.28) 0.36
Diffuse skin involvement 1.79 (1.06–3.02) 0.030
Time since onset of
scleroderma (per decade)
0.77 (0.55–1.08) 0.13
Arterial hypertension 2.22 (1.34–3.66) 0.002
Tendon friction rub 1.70 (0.83–3.48) 0.15
ACE inhibitors 2.07 (1.28–3.36) 0.003
SCL70-positive 0.98 (0.58–1.66) 0.94
ACA-positive 0.82 (0.45–1.49) 0.52
Glucocorticoids > 10 mg 1.49 (0.53–4.17) 0.45
PDE5 inhibitors 1.32 (0.60–2.87) 0.49
Table 3 Hazard ratios for SRC from a multivariable Cox
proportional hazard model with an interaction of arterial
hypertension and ACE inhibitors based on the medication
dataset
No. of renal
crises/patients
Hazard ratio
(95% CI)
P
value
Age (per decade) 78/6083 1.06 (0.87–1.28) 0.58
Sex (male) 1.29 (0.74–2.27) 0.37
Diffuse skin involvement 1.78 (1.05–3.01) 0.032
Time since onset of
scleroderma (per decade)
0.77 (0.55–1.08) 0.13
Arterial hypertension 2.41 (1.26–4.61) 0.008
Tendon friction rub 1.70 (0.83–3.48) 0.15
ACE inhibitors 2.28 (1.16–4.51) 0.018
SCL70-positive 0.98 (0.58–1.67) 0.95
ACA-positive 0.83 (0.46–1.50) 0.53
Glucocorticoids
> 10 mg
1.49 (0.53–4.17) 0.45
PDE5 inhibitors 1.31 (0.60–2.86) 0.50
Arterial hypertension#ACE
inhibitors
0.83 (0.32–2.13) 0.69
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make it a valuable alternative to ACEi at present. We
hope that a more frequent use of newer antihypertensive
drugs in the future will broaden our understanding of
their potential influence and safety regarding SRC in
hypertensive SSc patients.
Strengths and limitations
The EUSTAR database is the largest systematic and pro-
spective data collection regarding SSc and SRC.
In order to obtain reliable and consistent information,
we had to reduce the dataset considerably. Most notably,
we had to restrict the analysis of the medication on a
subset for which the documentation was consistent. Fur-
thermore, the main patient characteristics were not
changed and the analysis of all variables beside medica-
tion showed similar results. As to the nature of the data-
base indications for a specific treatment, e.g., ACEi
cannot be specified. Nevertheless, as ACEi remain
among the most frequently used antihypertensive drugs,
the conclusion to analyze its influence in relation to ar-
terial hypertension appears justified.
The measure of both outcome and exposure was im-
precise and not available on the same regular basis for
all patients. Furthermore, as the number of visits and the
time span of EUSTAR-documented visits differ between
patients with and without SRC, time-varying exposure
variables may not be observed with the same likelihood.
However, the most important findings were shown to be
stable within different definitions of the exposure (time-
varying versus baseline and anytime).
Antibodies to RNA polymerase III are known to be as-
sociated with SRC. Unfortunately, their measurement
has not been a routine procedure in most of the associ-
ated EUSTAR centers so far. Therefore, we were not
able to give additional information about RNA polymer-
ase III antibodies and their link to SRC as discussed here
but this should clearly be addressed in future studies.
Conclusion
ACEi in SSc patients with concomitant arterial hyperten-
sion display an independent risk factor for the develop-
ment of SRC. Still, they are the mainstay of treatment
once SRC is established. ARBs might be a safe option in
the treatment of arterial hypertension with a possibly
lower risk for development of SRC. Yet, the overall
safety of alternative antihypertensive drugs in SSc pa-
tients needs to be studied.
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multivariable Cox proportional hazard model with covariates observed at
any time before renal crisis based on the medication dataset.
Additional file 7: Table S4. Hazard ratios for renal crisis from a
multivariable Cox proportional hazard model when only patients enrolled
after 01.01.2009 are considered (i.e. the reduced medication dataset).
Additional file 8: Table S5. Subhazard ratios for renal crisis from a
multivariable competing risk model with death (without SRC) as
competing event based on the medication dataset.
Additional file 9: Table S6. Hazard ratios for the effect of ACEi on SRC
from Cox proportional hazard models adjusted for age, sex, disease
severity, and time since onset of scleroderma at baseline, and arterial
hypertension, tendon friction rub, SCL-70, ACA, glucocorticoids >10mg
and PDE5 inhibitors measured at baseline or at any time before renal cri-
sis using different propensity score methods, i.e. one-to-one matching, k-
nearest neighbors matching and inverse probability weighting.
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